Details of the Drug Reposition

General Information of This Drug (ID: DMUT9IQ)

Drug Name
Bupranolol   DMUT9IQ
Synonyms
BUPRANOLOL; Betadrenol; Bupranol; Bupranolol [INN:DCF]; Bupranololum; Bupranololum [INN-Latin]; HQIRNZOQPUAHHV-UHFFFAOYSA-N; KL 255; KL-255 [AS HYDROCHLORIDE]; Ophtorenin; SK&F 16805-A; 1-(tert-butylamino)-3-(2-chloro-5-methylphenoxy)propan-2-ol; 14556-46-8; 2-Propanol, 1-(2-chloro-5-methylphenoxy)-3-((1,1-dimethylethyl)amino)-; 2-Propanol, 1-(tert-butylamino)-3-(6-chloro-m-tolyloxy)-; 3-(tert-Butylamino)-1-(6-chloro-m-tolyloxy)-2-propanol; B 1312; BRN 2272923; C14H22ClNO2
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Glaucoma DISSBT20 N.A. Discontinued in Phase 2 [1]
High blood pressure DISY2OHH BA00 Discontinued in Phase 2 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01367275) Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF
2 ClinicalTrials.gov (NCT01652014) Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies